Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras

Cell

Volumn 168, Issue 5, 2017, Pages 890-903.e15

  Wang, Tim ^a,b,c   Yu, Haiyan ^b   Hughes, Nicholas W ^a,b,c   Liu, Bingxu ^a,b,c   Kendirli, Arek ^b,d   Klein, Klara ^b,d   Chen, Walter W ^a,b,c   Lander, Eric S ^a,b,e   Sabatini, David M ^a,b,c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AML; CRISPR; gene networks; genetic screens; RAS; synthetic lethality

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; SYNTHETIC DNA; CARRIER PROTEIN; COA6 PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; RAS PROTEIN;

ACUTE MYELOID LEUKEMIA; ANIMAL CELL; ARTICLE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; ENZYME SUBSTRATE; EPIGENETICS; ESSENTIAL GENE; FOLLOW UP; GENE FUNCTION; GENE INTERACTION; GENE REGULATORY NETWORK; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; HUMAN CELL; LETHAL GENE; MOUSE; MYELOID LEUKEMIA CELL LINE; NONHUMAN; ONCOGENE RAS; PRE B LYMPHOCYTE; PRIORITY JOURNAL; ANIMAL; GENETIC EPIGENESIS; GENETICS; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; EPIGENESIS, GENETIC; GENE REGULATORY NETWORKS; GENES, ESSENTIAL; HUMANS; LEUKEMIA, MYELOID, ACUTE; MAP KINASE SIGNALING SYSTEM; MICE; MITOCHONDRIAL PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RAS PROTEINS;

EID: 85011268687     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.01.013     Document Type: Article

References (62)

1. Aguirre, A.J., Meyers, R.M., Weir, B.A., Vazquez, F., Zhang, C.-Z., Ben-David, U., Cook, A., Ha, G., Harrington, W.F., Doshi, M.B., et al. Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting. 2016, Cancer Disc, 10.1158/2159-8290.CD-16-0154.
2. Ashworth, A., Lord, C.J., Reis-Filho, J.S., Genetic interactions in cancer progression and treatment. Cell 145 (2011), 30–38.
3. Barbie, D.A., Tamayo, P., Boehm, J.S., Kim, S.Y., Moody, S.E., Dunn, I.F., Schinzel, A.C., Sandy, P., Meylan, E., Scholl, C., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462 (2009), 108–112.
4. Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehár, J., Kryukov, G.V., Sonkin, D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483 (2012), 603–607.
5. Bassi, D.E., Fu, J., Lopez de Cicco, R., Klein-Szanto, A.J.P., Proprotein convertases: “master switches” in the regulation of tumor growth and progression. Mol. Carcinog. 44 (2005), 151–161.
6. Berger, A.H., Brooks, A.N., Wu, X., Shrestha, Y., Chouinard, C., Piccioni, F., Bagul, M., Kamburov, A., Imielinski, M., Hogstrom, L., et al. High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell 30 (2016), 214–228.
7. Blasco, Rafael B., Francoz, S., Santamaría, D., Cañamero, M., Dubus, P., Charron, J., Baccarini, M., Barbacid, M., c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 19 (2011), 652–663.
8. Boehm, J.S., Hahn, W.C., Towards systematic functional characterization of cancer genomes. Nat. Rev. Genet. 12 (2011), 487–498.
9. Chantranupong, L., Scaria, S.M., Saxton, R.A., Gygi, M.P., Shen, K., Wyant, G.A., Wang, T., Harper, J.W., Gygi, S.P., Sabatini, D.M., The CASTOR proteins are arginine sensors for the mTORC1 pathway. Cell 165 (2016), 153–164.
10. Chen, C., Itakura, E., Weber, K.P., Hegde, R.S., de Bono, M., An ER complex of ODR-4 and ODR-8/Ufm1 specific protease 2 promotes GPCR maturation by a Ufm1-independent mechanism. PLoS Genet., 10, 2014, e1004082.
11. Cheung, H.W., Cowley, G.S., Weir, B.A., Boehm, J.S., Rusin, S., Scott, J.A., East, A., Ali, L.D., Lizotte, P.H., Wong, T.C., et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Natl. Acad. Sci. USA 108 (2011), 12372–12377.
12. Chow, H.Y., Jubb, A.M., Koch, J.N., Jaffer, Z.M., Stepanova, D., Campbell, D.A., Duron, S.G., O'Farrell, M., Cai, K.Q., Klein-Szanto, A.J.P., et al. p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Res. 72 (2012), 5966–5975.
13. Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., Zhang, F., Multiplex genome engineering using CRISPR/Cas systems. Science 339 (2013), 819–823.
14. Cordeddu, V., Di Schiavi, E., Pennacchio, L.A., Ma'ayan, A., Sarkozy, A., Fodale, V., Cecchetti, S., Cardinale, A., Martin, J., Schackwitz, W., et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat. Genet. 41 (2009), 1022–1026.
15. Costanzo, M., VanderSluis, B., Koch, E.N., Baryshnikova, A., Pons, C., Tan, G., Wang, W., Usaj, M., Hanchard, J., Lee, S.D., et al. A global genetic interaction network maps a wiring diagram of cellular function. Science, 353, 2016 pii: aaf1420.
16. Courtois-Cox, S., Jones, S.L., Cichowski, K., Many roads lead to oncogene-induced senescence. Oncogene 27 (2008), 2801–2809.
17. Cowley, G.S., Weir, B.A., Vazquez, F., Tamayo, P., Scott, J.A., Rusin, S., East-Seletsky, A., Ali, L.D., Gerath, W.F.J., Pantel, S.E., et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci. Data, 1, 2014, 140035.
18. Cox, A.D., Fesik, S.W., Kimmelman, A.C., Luo, J., Der, C.J., Drugging the undruggable RAS: Mission possible?. Nat. Rev. Drug Discov. 13 (2014), 828–851.
19. Ebi, H., Costa, C., Faber, A.C., Nishtala, M., Kotani, H., Juric, D., Della Pelle, P., Song, Y., Yano, S., Mino-Kenudson, M., et al. PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proc. Natl. Acad. Sci. USA 110 (2013), 21124–21129.
20. Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N.J., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005), 917–921.
21. Feig, L.A., Cooper, G.M., Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins. Mol. Cell. Biol. 8 (1988), 2472–2478.
22. Floyd, B.J., Wilkerson, E.M., Veling, M.T., Minogue, C.E., Xia, C., Beebe, E.T., Wrobel, R.L., Cho, H., Kremer, L.S., Alston, C.L., et al. Mitochondrial protein interaction mapping identifies regulators of respiratory chain function. Mol. Cell 63 (2016), 621–632.
23. Forbes, S.A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43 (2015), D805–D811.
24. Garnett, M.J., Edelman, E.J., Heidorn, S.J., Greenman, C.D., Dastur, A., Lau, K.W., Greninger, P., Thompson, I.R., Luo, X., Soares, J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483 (2012), 570–575.
25. Garraway, L.A., Lander, E.S., Lessons from the cancer genome. Cell 153 (2013), 17–37.
26. Giaever, G., Chu, A.M., Ni, L., Connelly, C., Riles, L., Véronneau, S., Dow, S., Lucau-Danila, A., Anderson, K., André, B., et al. Functional profiling of the Saccharomyces cerevisiae genome. Nature 418 (2002), 387–391.
27. Gibson, D.G., Young, L., Chuang, R.Y., Venter, J.C., Hutchison, C.A. 3rd, Smith, H.O., Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6 (2009), 343–345.
28. Gilbert, L.A., Horlbeck, M.A., Adamson, B., Villalta, J.E., Chen, Y., Whitehead, E.H., Guimaraes, C., Panning, B., Ploegh, H.L., Bassik, M.C., et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159 (2014), 647–661.
29. Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K.R., MacLeod, G., Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell 163 (2015), 1515–1526.
30. Horlbeck, M.A., Gilbert, L.A., Villalta, J.E., Adamson, B., Pak, R.A., Chen, Y., Fields, A.P., Park, C.Y., Corn, J.E., Kampmann, M., Weissman, J.S., Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. eLife, 5, 2016, e19760.
31. Hughes, T.R., Marton, M.J., Jones, A.R., Roberts, C.J., Stoughton, R., Armour, C.D., Bennett, H.A., Coffey, E., Dai, H., He, Y.D., et al. Functional discovery via a compendium of expression profiles. Cell 102 (2000), 109–126.
32. Kaelin, W.G. Jr., The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5 (2005), 689–698.
33. G12D). Cancer Discov. 1 (2011), 128–136.
34. Kim, H.S., Mendiratta, S., Kim, J., Pecot, C.V., Larsen, J.E., Zubovych, I., Seo, B.Y., Kim, J., Eskiocak, B., Chung, H., et al. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell 155 (2013), 552–566.
35. King, A.J., Sun, H., Diaz, B., Barnard, D., Miao, W., Bagrodia, S., Marshall, M.S., The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature 396 (1998), 180–183.
36. Klijn, C., Durinck, S., Stawiski, E.W., Haverty, P.M., Jiang, Z., Liu, H., Degenhardt, J., Mayba, O., Gnad, F., Liu, J., et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33 (2015), 306–312.
37. Koike-Yusa, H., Li, Y., Tan, E.P., Velasco-Herrera, Mdel.C., Yusa, K., Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat. Biotechnol. 32 (2014), 267–273.
38. Komatsu, M., Chiba, T., Tatsumi, K., Iemura, S., Tanida, I., Okazaki, N., Ueno, T., Kominami, E., Natsume, T., Tanaka, K., A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. EMBO J. 23 (2004), 1977–1986.
39. Lawrence, M.S., Stojanov, P., Mermel, C.H., Robinson, J.T., Garraway, L.A., Golub, T.R., Meyerson, M., Gabriel, S.B., Lander, E.S., Getz, G., Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505 (2014), 495–501.
40. Lehrbach, N.J., Ruvkun, G., Proteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1. eLife, 5, 2016, e17721.
41. Luo, J., Emanuele, M.J., Li, D., Creighton, C.J., Schlabach, M.R., Westbrook, T.F., Wong, K.-K., Elledge, S.J., A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137 (2009), 835–848.
42. Luo, J., Solimini, N.L., Elledge, S.J., Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136 (2009), 823–837.
43. Marcotte, R., Brown, K.R., Suarez, F., Sayad, A., Karamboulas, K., Krzyzanowski, P.M., Sircoulomb, F., Medrano, M., Fedyshyn, Y., Koh, J.L.Y., et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov. 2 (2012), 172–189.
44. Munoz, D.M., Cassiani, P.J., Li, L., Billy, E., Korn, J.M., Jones, M.D., Golji, J., Ruddy, D.A., Yu, K., McAllister, G., et al. CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions. Cancer Discov. 6 (2016), 900–913.
45. Quentmeier, H., Reinhardt, J., Zaborski, M., Drexler, H.G., FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 17 (2003), 120–124.
46. Quentmeier, H., MacLeod, R.A.F., Zaborski, M., Drexler, H.G., JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 20 (2006), 471–476.
47. Radhakrishnan, S.K., den Besten, W., Deshaies, R.J., p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition. eLife, 3, 2014, e01856.
48. Rodriguez-Viciana, P., Oses-Prieto, J., Burlingame, A., Fried, M., McCormick, F., A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Mol. Cell 22 (2006), 217–230.
49. Schlabach, M.R., Luo, J., Solimini, N.L., Hu, G., Xu, Q., Li, M.Z., Zhao, Z., Smogorzewska, A., Sowa, M.E., Ang, X.L., et al. Cancer proliferation gene discovery through functional genomics. Science 319 (2008), 620–624.
50. Shalem, O., Sanjana, N.E., Hartenian, E., Shi, X., Scott, D.A., Mikkelsen, T.S., Heckl, D., Ebert, B.L., Root, D.E., Doench, J.G., Zhang, F., Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343 (2014), 84–87.
51. Starita, L.M., Young, D.L., Islam, M., Kitzman, J.O., Gullingsrud, J., Hause, R.J., Fowler, D.M., Parvin, J.D., Shendure, J., Fields, S., Massively parallel functional analysis of BRCA1 RING domain variants. Genetics 200 (2015), 413–422.
52. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005), 15545–15550.
53. Swarthout, J.T., Lobo, S., Farh, L., Croke, M.R., Greentree, W.K., Deschenes, R.J., Linder, M.E., DHHC9 and GCP16 constitute a human protein fatty acyltransferase with specificity for H- and N-Ras. J. Biol. Chem. 280 (2005), 31141–31148.
54. Toledo, C.M., Ding, Y., Hoellerbauer, P., Davis, R.J., Basom, R., Girard, E.J., Lee, E., Corrin, P., Hart, T., Bolouri, H., et al. Genome-wide CRISPR-Cas9 screens reveal loss of redundancy between PKMYT1 and WEE1 in glioblastoma stem-like cells. Cell Rep. 13 (2015), 2425–2439.
55. Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D.R., Pimentel, H., Salzberg, S.L., Rinn, J.L., Pachter, L., Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 7 (2012), 562–578.
56. Tsang, Y.H., Dogruluk, T., Tedeschi, P.M., Wardwell-Ozgo, J., Lu, H., Espitia, M., Nair, N., Minelli, R., Chong, Z., Chen, F., et al. Functional annotation of rare gene aberration drivers of pancreatic cancer. Nat. Commun., 7, 2016, 10500.
57. Tzelepis, K., Koike-Yusa, H., De Braekeleer, E., Li, Y., Metzakopian, E., Dovey, O.M., Mupo, A., Grinkevich, V., Li, M., Mazan, M., et al. A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Rep. 17 (2016), 1193–1205.
58. Wang, T., Wei, J.J., Sabatini, D.M., Lander, E.S., Genetic screens in human cells using the CRISPR-Cas9 system. Science 343 (2014), 80–84.
59. Wang, T., Birsoy, K., Hughes, N.W., Krupczak, K.M., Post, Y., Wei, J.J., Lander, E.S., Sabatini, D.M., Identification and characterization of essential genes in the human genome. Science 350 (2015), 1096–1101.
60. Welch, H.C.E., Coadwell, W.J., Ellson, C.D., Ferguson, G.J., Andrews, S.R., Erdjument-Bromage, H., Tempst, P., Hawkins, P.T., Stephens, L.R., P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. Cell 108 (2002), 809–821.
61. Whitesell, L., Lindquist, S.L., HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5 (2005), 761–772.
62. Whyte, D.B., Kirschmeier, P., Hockenberry, T.N., Nunez-Oliva, I., James, L., Catino, J.J., Bishop, W.R., Pai, J.K., K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272 (1997), 14459–14464.